FBIOP Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
NASDAQ · Biotechnology · عرض على SEC EDGAR ↗ إغلاق أكتوبر 2, 2026 10-K/10-Q أغسطس 13, 2026
$16,86
· % من نطاق 52 أسبوعًا
· فوق الحد الأدنى
· إلى مرتفع
$6,27أدنى 52 أسبوعًا
$21,43أعلى 52 أسبوعًا
القيمة السوقية (الربع الأخير)
$562M
P/E (سنوي حالي)
6.2
ربح السهم (سنوي حالي)
$2.70
الإيرادات (سنوي حالي)
$68M
شاراتك
نطاق 52 أسبوعًا
$6–$21
تقييم المحللين
BUY
السعر المستهدف
·
P/E
6.2
ROE
107.5%
هامش صافي الربح
163.3%
شريط الشارات الخاص بك فارغ — قم بتثبيت مقياس في أي مكان على هذه الصفحة.
FBIOP لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
السعر
$16.86
القيمة السوقية (الربع الأخير)
$562M
P/E (سنوي حالي)
6.2
ربح السهم (سنوي حالي)
$2.70
الإيرادات (سنوي حالي)
$68M
عائد التوزيعات
0.12%
ROE (سنوي حالي)
107.5%
D/E الدين/حقوق الملكية (الربع الأخير)
0.0
نطاق 52 أسبوعًا
$6–$21
FBIOP مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
نطاق
أشرطة
تتكيف دقة الشريط مع الفترة المحددة - مرر مؤشر الفأرة فوق الرسم البياني لرؤية الافتتاح/الأعلى/الأدنى/الإغلاق للشريط.
حول Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock نظرة عامة على الشركة من ويكيبيديا
Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.
History
The company was founded in 2006 under the name Coronado Biosciences, initially as an oncology company. In 2011, it was announced that Coronado raised $47.4 million in funding. Shortly thereafter it became a public company by registering all of its private shares as common stock. The company changed its name to Fortress Biotech in April 2015.
In November 2019, Fortress Biotech was ranked number 10 in the 2019 Deloitte Technology Fast 500 annual rankings.
Subsidiaries
Fortress Bio has 10 biopharmaceutical subsidiary companies which cover a range of medical therapy areas, including potential cancer treatments and therapies for rare diseases and conditions. These subsidiaries include Aevitas Therapeutics (formed in 2017), Avenue Therapeutics (formed in 2015), Caelum Biosciences (formed in 2017), Cellvation (formed in 2016), Checkpoint Therapeutics (formed in 2015), Cyprium Therapeutics (formed in 2017), Helocyte (formed in 2015), Journey Medical Corporation (formed in 2014), Mustang Bio (formed in 2015), Tamid Bio (formed in 2017) and Baergic Bio (formed in 2019).
Products
Fortress Bio’s marketed products are developed and commercialized by its subsidiary Journey Medical Corporation. These include Targadox tablets indicated for acne, eczema emollient Ceracade, wound cream Luxamend, topical corticosteroid Triderm, topical broad-spectrum antifungal solution Exelderm, Ala-Quin topical cream for skin conditions, and Ala-Scalp hydrocortisone lotion for skin conditions.
== References ==
المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗
قطاعHealthcare
صناعةBiotechnology
موظفون78
بلدUS
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
الإيرادات$63M2021-12-31 → 2025-12-31
ربح السهم$-0.072021-12-31 → 2025-12-31
التدفق النقدي الحر·2021-12-31 → 2024-12-31
هامش صافي163.3%2021-12-31 → 2025-12-31
التقييم والنسب
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
| المقياس | اتجاه 5 سنوات | FBIOP | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| P/E (سنوي حالي) | 6.2 | · | · | · | |
| السعر/المبيعات (سنوي حالي) | 8.2 | · | 16.1 | مقوّم بأقل من قيمته | |
| السعر / القيمة الدفترية (الربع الأخير) | 3.4 | · | 2.3 | مبالغ في تقييمه | |
| Price / Cash Flow (السعر / التدفق النقدي) | -8.0 | · | · | · | |
| السعر / القيمة الدفترية الملموسة (الربع الأخير) | 4.1 | · | · | · |
يتم حساب الوسيط النظير على أساس موحد لكل مقياس وقد لا يتطابق دائمًا مع الأساس السنوي الحالي/الربع الأخير المعروض لهذا السهم.
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
| المقياس | اتجاه 5 سنوات | FBIOP | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| هامش التشغيل (سنوي حالي) | -42.6% | · | -461.4% | من الدرجة الأولى | |
| EBITDA Margin (هامش EBITDA) | -111.0% | · | -461.4% | من الدرجة الأولى | |
| هامش ما قبل الضريبة (سنوي حالي) | 213.0% | · | -799.5% | من الدرجة الأولى | |
| هامش صافي الربح (سنوي حالي) | 163.3% | · | -412.5% | من الدرجة الأولى | |
| العائد على الأصول (سنوي حالي) | 46.9% | · | -36.6% | من الدرجة الأولى | |
| ROE (سنوي حالي) | 107.5% | · | -61.0% | من الدرجة الأولى | |
| ROIC | -138.2% | · | -64.8% | ضعيف |
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
| المقياس | اتجاه 5 سنوات | FBIOP | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| الدين / حقوق الملكية (الربع الأخير) | 0.0 | · | 0.0 | ديون مرتفعة | |
| النسبة الحالية (الربع الأخير) | 4.0 | · | 4.9 | سيولة منخفضة | |
| Quick Ratio (النسبة السريعة) | 2.2 | · | 2.7 | سيولة قوية |
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
| المقياس | اتجاه 5 سنوات | FBIOP | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| Revenue YoY (الإيرادات مقارنة بالعام السابق) | 9.7% | · | · | · | |
| Revenue CAGR 3Y (معدل نمو الإيرادات السنوي المركب لـ 3 سنوات) | -5.8% | · | · | · | |
| Revenue CAGR 5Y (معدل نمو الإيرادات السنوي المركب لـ 5 سنوات) | 6.8% | · | · | · |
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
| المقياس | اتجاه 5 سنوات | FBIOP | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| Asset Turnover (دوران الأصول) | 0.4 | · | 0.1 | من الدرجة الأولى | |
| Inventory Turnover (دوران المخزون) | 1.7 | · | · | · | |
| Receivables Turnover (دوران المستحقات) | 3.2 | · | 5.6 | ضعيف | |
| Revenue / Employee (الإيرادات / الموظف) | ≈$811.1K | · | · | · |
القيمة · ≈ متوسط 5 سنوات · متوسط الصناعة · حكم مقارنة بالمتوسط
التوزيعات العائد، نسبة التوزيع، تاريخ توزيع الأرباح، معدل النمو السنوي المركب لمدة 5 سنوات
عائد الأرباح0.12%
نسبة التوزيع9.7%
العائد السنوي≈$2.34
| تاريخ الاستحقاق | المبلغ | العملة | العائد |
|---|---|---|---|
| يونيو 14, 2024 | $0,20 | USD | ≈14.0% |
| مايو 14, 2024 | $0,20 | USD | ≈14.2% |
| إبريل 12, 2024 | $0,20 | USD | ≈13.4% |
| مارس 14, 2024 | $0,20 | USD | ≈14.0% |
| فبراير 14, 2024 | $0,20 | USD | ≈14.7% |
| يناير 11, 2024 | $0,20 | USD | ≈18.0% |
| ديسمبر 14, 2023 | $0,20 | USD | ≈18.3% |
| نوفمبر 14, 2023 | $0,20 | USD | ≈20.8% |
| أكتوبر 12, 2023 | $0,20 | USD | ≈19.7% |
| سبتمبر 14, 2023 | $0,20 | USD | ≈19.8% |
| أغسطس 14, 2023 | $0,20 | USD | ≈13.8% |
| يوليو 13, 2023 | $0,20 | USD | ≈13.6% |
| يونيو 14, 2023 | $0,20 | USD | ≈13.4% |
| مايو 12, 2023 | $0,20 | USD | ≈12.5% |
| إبريل 13, 2023 | $0,20 | USD | ≈12.7% |
| مارس 14, 2023 | $0,20 | USD | ≈11.9% |
| فبراير 14, 2023 | $0,20 | USD | ≈12.1% |
| يناير 12, 2023 | $0,20 | USD | ≈12.2% |
| ديسمبر 14, 2022 | $0,20 | USD | ≈11.6% |
| نوفمبر 14, 2022 | $0,20 | USD | ≈11.6% |
سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
متوسط المفاجأة
-50.7%
| الفترة | تقرير | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|---|
| 30 يونيو، 2026 | $-0.08 | $-0.20 | 60.8% | |
| 31 مارس، 2026 | $-1.13 | $-0.22 | -403.6% | |
| 31 ديسمبر، 2025 | $-0.01 | $0.11 | -108.9% | |
| 30 سبتمبر، 2025 | $0.11 | $-0.43 | 125.7% | |
| 30 يونيو، 2025 | $-0.50 | $-0.37 | -36.2% | |
| 31 مارس، 2025 | $-0.48 | $-0.50 | 4.9% | |
| 31 ديسمبر، 2024 | $-0.75 | $-0.77 | 2.4% |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63M | $58M | $85M | $76M | $69M | $46M | $37M | $27M | $17M | $16M | $863.0K | $0 | |
| Cost of Revenue | $21M | $21M | $23M | $31M | $32M | $15M | $11M | $6M | $4M | $790.0K | $0 | · | |
| R&D Expense | · | · | $106M | $135M | $129M | $64M | $81M | $87M | $48M | $35M | $30M | $10M | |
| SG&A Expense | $96M | $88M | $91M | $114M | $87M | $61M | $56M | $53M | $51M | $28M | $19M | $10M | |
| Operating Expenses | $133M | $168M | $227M | $279M | $257M | $140M | $147M | $147M | $107M | $82M | $51M | $21M | |
| Operating Income | $-70M | $-110M | $-142M | $-204M | $-189M | $-94M | $-111M | $-120M | $-90M | $-66M | $-51M | $-21M | |
| Interest Expense | · | · | · | · | · | · | · | · | $6M | $4M | $1M | $1M | |
| Interest Income | $2M | $3M | $3M | $1M | $649.0K | $2M | $3M | $1M | $819.0K | $298.0K | $245.0K | $662.0K | |
| Other Non-op | $18M | $1M | $-3M | $1M | $24M | $-9M | $9M | $-11M | $-8M | $-6M | $-3M | $266.0K | |
| Pretax Income | $-34M | $-121M | $-154M | $-213M | $-164M | $-103M | $-102M | $-131M | $-98M | $-71M | $-54M | · | |
| Income Tax | $-620.0K | $312.0K | $521.0K | $449.0K | $500.0K | $500.0K | $0 | $0 | $2M | $0 | $0 | · | |
| Net Income | $7M | $-46M | $-61M | $-87M | $-65M | $-47M | $-40M | $-84M | $-67M | $-55M | $-48M | $-20M | |
| EPS (Basic) | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-0.79 | · | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-0.79 | · | · | · | · | · | · | · | |
| Shares (Basic) | 27,901,889 | 20,784,334 | 8,110,906 | 5,924,967 | 81,700,220 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 27,901,889 | 20,784,334 | 8,110,906 | 5,924,967 | 81,700,220 | · | · | · | · | · | · | · | |
| EBITDA | $-70M | $-110M | $-142M | $-204M | $-189M | $-94M | $-111M | $-120M | $-100M | $-65M | $-51M | · |
الميزانية العمومية
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $79M | $57M | $81M | $178M | $306M | $233M | $137M | $66M | $95M | $105M | $98M | $50M | |
| Short-term Investments | · | · | · | · | · | · | $0 | $18M | $36M | $0 | · | $20M | |
| Receivables | $30M | $10M | $15M | $28M | $23M | $24M | $14M | $5M | $8M | $2M | $0 | · | |
| Inventory | $10M | $14M | $10M | $14M | $10M | $1M | $857.0K | $678.0K | $171.0K | $203.0K | $0 | · | |
| Prepaid Expense | $5M | $7M | $10M | $10M | $7M | $7M | $4M | $7M | $6M | $9M | $2M | $702.0K | |
| Current Assets | $124M | $90M | $117M | $230M | $346M | $266M | $156M | $111M | $183M | $110M | $100M | $70M | |
| PP&E (Net) | $3M | $3M | $7M | $13M | $15M | $12M | $12M | $12M | $7M | $7M | $309.0K | $52.0K | |
| PP&E (Gross) | $8M | $15M | $15M | $25M | $24M | $19M | $17M | $15M | $8M | · | $377.0K | $94.0K | |
| Accum. Depreciation | $3M | $10M | $9M | $12M | $9M | $7M | $4M | $3M | $1M | · | $68.0K | $42.0K | |
| Goodwill | · | · | · | · | · | · | · | · | $19M | $19M | $0 | · | |
| Intangibles | $28M | $32M | $20M | $27M | $13M | $15M | $7M | $1M | $883.0K | $17M | $1M | $0 | |
| Other Non-current Assets | $401.0K | $731.0K | $4M | $973.0K | $1M | $1M | $1M | $276.0K | $258.0K | $394.0K | $43.0K | $64.0K | |
| Total Assets | $186M | $144M | $168M | $294M | $397M | $333M | $226M | $141M | $246M | $171M | $119M | $89M | |
| Accounts Payable | $14M | $32M | $35M | $57M | $47M | $11M | $35M | $34M | $27M | $2M | $10M | $366.0K | |
| Accrued Liabilities | $47M | $66M | $74M | $97M | $91M | $45M | $25M | $16M | $18M | $10M | $9M | $4M | |
| Short-term Debt | · | · | · | · | · | $0 | $7M | · | · | · | · | $0 | |
| Current Liabilities | $50M | $71M | $85M | $128M | $101M | $52M | $46M | $56M | $71M | $57M | $11M | $4M | |
| Capital Leases | $13M | $15M | $18M | $22M | $21M | $23M | $24M | $0 | · | · | · | · | |
| Deferred Tax | · | · | $233.0K | $0 | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $5M | $5M | $5M | $584.0K | $722.0K | |
| Total Liabilities | $123M | $146M | $166M | $244M | $171M | $136M | $154M | $121M | $125M | $88M | $34M | $19M | |
| Long-term Debt | $54M | $58M | $61M | $92M | $43M | $52M | $85M | $84M | $68M | $30M | $24M | $14M | |
| Total Debt | · | · | · | · | · | $0 | · | · | · | · | · | · | |
| Common Stock | $31.0K | $28.0K | $15.0K | $7.0K | $101.0K | $95.0K | $74.0K | $58.0K | $51.0K | $49.0K | $47.0K | $46.0K | |
| Paid-in Capital | $784M | $764M | $717M | $676M | $656M | $583M | $462M | $397M | $364M | $284M | $247M | $212M | |
| Retained Earnings | $-734M | $-741M | $-695M | $-634M | $-547M | $-483M | $-436M | $-396M | $-312M | $-245M | $-190M | $-142M | |
| Stockholders' Equity | $50M | $23M | $23M | $42M | $109M | $100M | $26M | $2M | $53M | $38M | $57M | $71M | |
| Liabilities + Equity | $186M | $144M | $168M | $294M | $397M | $333M | $226M | $141M | $246M | $171M | $119M | $89M | |
| Shares Outstanding | 31,364,094 | 27,908,839 | 15,093,053 | 7,366,283 | 101,435,505 | 94,877,492 | 74,027,425 | 57,845,447 | 50,991,285 | 48,932,023 | 47,147,032 | 46,494,034 |
التدفق النقدي
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | $1M | $944.0K | $26.0K | $23.0K | |
| Stock-based Comp | $29M | $33M | $17M | $23M | $19M | $13M | $13M | $15M | $13M | $12M | $14M | $6M | |
| Deferred Tax | · | · | · | · | · | · | · | $0 | $0 | $-73.0K | $0 | $0 | |
| Amort. of Intangibles | $4M | $3M | $4M | $4M | · | $1M | $1M | · | $2M | $0 | $0 | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | $-34M | $-4M | $14M | · | |
| Operating Cash Flow | $-66M | $-80M | $-128M | $-179M | $-117M | $-84M | $-95M | $-99M | $-81M | $-46M | $-20M | $-16M | |
| CapEx | · | $0 | $63.0K | $3M | $5M | $2M | $2M | $7M | $648.0K | $6M | $283.0K | $0 | |
| Investing Cash Flow | $10M | $-15M | $-2M | $-23M | $41M | $-7M | $20M | $19M | $-40M | $-6M | $8M | · | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Stock Issued | $1M | $4M | $2M | $6M | $9M | $46M | $21M | $10M | · | $0 | $0 | $4M | |
| Stock Repurchased | · | · | · | · | · | $70.0K | $0 | · | · | · | · | · | |
| Net Stock Activity | $1M | $4M | $2M | $6M | $9M | $47M | · | $10M | · | $0 | $0 | · | |
| Dividends Paid | $664.0K | $694.0K | $736.0K | $749.0K | $749.0K | $237.0K | $0 | · | · | · | · | · | |
| Financing Cash Flow | $77M | $71M | $33M | $75M | $149M | $172M | $147M | $51M | $150M | $43M | $61M | · | |
| Net Change in Cash | $22M | $-25M | $-98M | $-127M | $73M | $82M | $72M | $-29M | $29M | $-9M | $48M | $-50M | |
| Taxes Paid | $49.0K | $120.0K | $-55.0K | $858.0K | $993.0K | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-80M | $-128M | $-182M | $-121M | $-86M | $-97M | $-106M | $-88M | $-52M | $-21M | · | |
| Levered FCF | · | · | · | · | · | · | · | · | $-93M | · | · | · |
الربحية
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -111.0% | -191.4% | -168.4% | -268.8% | -274.1% | -206.7% | -302.5% | -446.4% | -53.9% | -398.7% | -5855.3% | · | |
| Net Margin | 10.8% | -79.8% | -71.8% | -114.3% | -94.1% | -102.0% | -109.1% | -313.0% | -35.6% | -334.3% | -5611.6% | · | |
| Pretax Margin | -53.0% | -209.0% | -181.8% | -281.8% | -238.9% | -225.6% | -277.5% | -486.6% | -52.4% | · | · | · | |
| EBITDA Margin | -111.0% | -191.4% | -168.4% | -268.8% | -274.1% | -206.7% | -302.5% | -446.4% | -53.3% | -393.0% | -5852.3% | · | |
| ROA | 4.1% | -33.9% | -26.3% | -25.1% | -17.7% | -16.7% | -21.8% | -43.5% | -32.1% | -34.8% | -47.1% | · | |
| ROE | 18.8% | -203.2% | -188.7% | -115.1% | -61.9% | -73.5% | -284.8% | -309.2% | -146.9% | -115.6% | -76.0% | · | |
| ROIC | -138.2% | -486.7% | -633.5% | -488.9% | -174.0% | -94.1% | -422.7% | -6479.3% | -195.5% | · | · | · |
السيولة والملاءة
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.5 | 1.3 | 1.4 | 1.8 | 3.4 | 5.5 | 3.4 | 2.0 | 2.7 | 1.9 | 9.4 | · | |
| Quick Ratio | 2.2 | 0.9 | 1.1 | 1.6 | 3.3 | 5.3 | 3.3 | 1.6 | 2.3 | 1.6 | 9.3 | · | |
| Debt / Equity | · | · | · | · | · | 0.0 | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | -17.3 | -17.8 | -34.1 | · |
الكفاءة
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.9 | 0.1 | 0.0 | · | |
| Inventory Turnover | 1.7 | 1.7 | 2.2 | 2.6 | 5.7 | 12.9 | 13.7 | 14.4 | 19.6 | -7.8 | · | · | |
| Receivables Turnover | 3.2 | 4.5 | 3.9 | 3.0 | 2.9 | 2.8 | 3.8 | 4.1 | 39.1 | 18.0 | · | · |
لكل سهم
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.59 | $0.81 | $1.49 | $0.38 | $1.07 | $1.06 | $0.35 | $0.03 | $1.03 | $0.79 | $1.21 | · | |
| Revenue / Share | $2.27 | $2.77 | $10.42 | $0.85 | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-2.36 | $-3.86 | $-15.81 | $-2.02 | · | · | · | · | · | · | · | · | |
| Cash / Share | $2.53 | $2.05 | $5.36 | $1.61 | $3.01 | $2.46 | $1.85 | $1.13 | $2.23 | $1.80 | $2.08 | · | |
| EPS (TTM) | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-0.79 | · | · | · | · | · | · | · |
معدلات النمو
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 9.7% | -31.8% | 11.6% | 10.1% | 50.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -5.8% | -5.7% | 22.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 22.9% | · | · | · | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا)
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $63M | $58M | $85M | $76M | $69M | $46M | $37M | $27M | $17M | $16M | $863.0K | $0 | |
| Net Income TTM | $7M | $-46M | $-61M | $-87M | $-65M | $-47M | $-40M | $-84M | $-67M | $-55M | $-48M | $-20M | |
| Market Cap | $298M | $186M | $179M | $1.95B | $2.63B | $1.84B | $1.52B | $832M | $1.16B | · | · | · | |
| Enterprise Value | · | · | · | · | · | $1.61B | · | · | · | · | · | · | |
| P/E | -135.6 | -2.5 | -1.4 | -1.1 | -32.8 | · | · | · | · | · | · | · | |
| P/S | 4.7 | 3.2 | 2.1 | 25.7 | 38.2 | 40.3 | 41.4 | 31.0 | 67.3 | · | · | · | |
| P/B | 6.0 | 8.2 | 7.9 | 46.7 | 24.2 | 18.3 | 57.8 | 449.4 | 22.1 | · | · | · | |
| P / Tangible Book | 13.4 | · | 79.4 | 134.3 | 27.3 | 21.5 | · | · | · | · | · | · | |
| P / Cash Flow | -4.5 | -2.3 | -1.4 | -10.9 | -22.5 | -22.0 | -16.0 | -8.4 | -13.6 | · | · | · | |
| P / FCF | · | -2.3 | -1.4 | -10.7 | -21.7 | -21.5 | -15.6 | -7.9 | -13.3 | · | · | · | |
| EV / EBITDA | · | · | · | · | · | -17.0 | · | · | · | · | · | · | |
| EV / FCF | · | · | · | · | · | -18.8 | · | · | · | · | · | · | |
| EV / Revenue | · | · | · | · | · | 35.2 | · | · | · | · | · | · | |
| Dividend Yield | 0.22% | 0.37% | 0.41% | 0.04% | 0.03% | 0.01% | 0.00% | · | · | · | · | · | |
| Earnings Yield | -0.74% | -40.5% | -71.4% | -90.5% | -3.0% | · | · | · | · | · | · | · | |
| Payout Ratio | 9.7% | -1.5% | -1.2% | -0.87% | -1.2% | -0.51% | · | · | · | · | · | · | |
| Annual Payout | $664.0K | $694.0K | $736.0K | $749.0K | $749.0K | $237.0K | $0 | · | · | · | · | · |
قائمة الدخل
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19M | $16M | $16M | $18M | $16M | $13M | $15M | $15M | $15M | $13M | $20M | $35M | $17M | $12M | $16M | $17M | |
| Cost of Revenue | $6M | $6M | $5M | $6M | $5M | $5M | $5M | $4M | $6M | $6M | $2M | $6M | $8M | $6M | $8M | $7M | |
| R&D Expense | · | · | · | · | · | · | · | $9M | $13M | $25M | · | $20M | $32M | $40M | $35M | $30M | |
| SG&A Expense | $21M | $16M | $15M | $17M | $39M | $26M | $27M | $22M | $21M | $18M | $19M | $22M | $24M | $25M | $28M | $30M | |
| Operating Expenses | $29M | $24M | $21M | $24M | $53M | $35M | $39M | $37M | $43M | $50M | $40M | $49M | $67M | $71M | $71M | $67M | |
| Operating Income | $-10M | $-8M | $-5M | $-7M | $-36M | $-22M | $-24M | $-22M | $-28M | $-37M | $-20M | $-14M | $-50M | $-59M | $-55M | $-51M | |
| Interest Income | $2M | $570.0K | $637.0K | $736.0K | $622.0K | $490.0K | $527.0K | $589.0K | $734.0K | $833.0K | $705.0K | $547.0K | $715.0K | $1M | $687.0K | $419.0K | |
| Other Non-op | $11M | $1M | $-20.0K | $18M | $-62.0K | $-12.0K | $-14.0K | $1M | $282.0K | $-21.0K | $-5M | $620.0K | $395.0K | $304.0K | $6M | $648.0K | |
| Pretax Income | $922.0K | $142M | $-6M | $9M | $-12M | $-25M | $-26M | $-27M | · | · | $-29M | $-11M | · | · | $-57M | $-53M | |
| Income Tax | $320.0K | $5M | $-646.0K | $26.0K | $0 | $0 | $243.0K | $69.0K | $0 | $0 | $380.0K | $141.0K | $0 | $0 | $449.0K | $0 | |
| Net Income | $-468.0K | $110M | $-4M | $6M | $15M | $-11M | $-7M | $-13M | $-11M | $-15M | $-9M | $-5M | $-25M | $-22M | $-27M | $-23M | |
| EPS (Basic) | $-0.08 | $3.44 | $-0.22 | $0.13 | $0.50 | $-0.48 | $-0.16 | $-0.76 | $-0.73 | $-1.04 | $-0.41 | $-0.94 | $-3.65 | $-3.47 | $-11.39 | $-4.11 | |
| EPS (Diluted) | $-0.08 | $2.82 | $-0.15 | $0.11 | $0.45 | $-0.48 | $-0.16 | $-0.76 | $-0.73 | $-1.04 | $-3.67 | $-0.94 | $-3.65 | $-0.21 | $-11.42 | $-4.11 | |
| Shares (Basic) | 31,791,173 | 31,540,595 | · | 27,244,474 | 26,879,380 | 26,450,218 | · | 19,697,290 | 18,316,874 | 17,151,945 | · | 7,498,653 | 7,377,332 | 6,792,376 | · | 5,961,663 | |
| Shares (Diluted) | 31,791,173 | 38,412,716 | · | 33,100,961 | 29,824,182 | 26,450,218 | · | 19,697,290 | 18,316,874 | 17,151,945 | · | 7,498,653 | 7,377,332 | 101,885,648 | · | 5,961,663 | |
| EBITDA | $-10M | $-8M | · | $-7M | $-36M | $-22M | · | $-22M | $-28M | $-37M | · | $-14M | $-50M | $-59M | · | $-51M |
الميزانية العمومية
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $197M | $256M | $79M | $86M | $74M | $91M | $57M | $59M | $76M | $84M | $81M | $72M | $78M | $152M | $178M | $208M | |
| Receivables | $36M | $25M | $30M | $18M | $16M | $18M | $10M | $11M | $10M | $10M | $15M | $8M | $17M | $28M | $28M | $29M | |
| Inventory | $8M | $9M | $10M | $12M | $13M | $12M | $14M | $12M | $10M | $11M | $10M | $11M | $12M | $13M | $14M | $15M | |
| Prepaid Expense | $4M | $5M | $5M | $2M | $7M | $5M | $7M | $3M | $5M | $12M | $10M | $6M | $7M | $8M | $10M | $6M | |
| Current Assets | $246M | $295M | $124M | $119M | $110M | $127M | $90M | $86M | $103M | $117M | $117M | $98M | $128M | $202M | $230M | $258M | |
| PP&E (Net) | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $6M | $7M | $7M | $7M | $12M | $13M | $14M | |
| PP&E (Gross) | $7M | $7M | $8M | $8M | $8M | $8M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $25M | $25M | $25M | |
| Accum. Depreciation | $3M | $2M | $3M | $3M | $3M | $3M | $10M | $12M | $10M | $9M | $9M | $9M | $8M | $13M | $12M | $12M | |
| Intangibles | $26M | $26M | $28M | $29M | $30M | $31M | $32M | $18M | $19M | $19M | $20M | $21M | $22M | $26M | $27M | $28M | |
| Other Non-current Assets | $1M | $740.0K | $401.0K | $18M | $3M | $3M | $731.0K | $3M | $3M | $4M | $4M | $5M | $4M | $943.0K | $973.0K | $1M | |
| Total Assets | $317M | $357M | $186M | $181M | $160M | $178M | $144M | $127M | $146M | $165M | $168M | $151M | $181M | $264M | $294M | $324M | |
| Accounts Payable | $12M | $14M | $14M | $19M | $20M | $28M | $32M | $34M | $38M | $42M | $35M | $45M | $49M | $66M | $57M | $56M | |
| Accrued Liabilities | $49M | $93M | $47M | $45M | $49M | $66M | $66M | $64M | $69M | $76M | $74M | $81M | $99M | $105M | $97M | $94M | |
| Short-term Debt | $5M | $2M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $62M | $103M | $50M | $54M | $58M | $74M | $71M | $70M | $76M | $88M | $85M | $97M | $129M | $129M | $128M | $106M | |
| Capital Leases | $11M | $12M | $13M | $13M | $13M | $14M | $15M | $15M | $16M | $18M | $18M | $19M | $20M | $21M | $22M | $21M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | |
| Other Non-current Liabilities | $3M | $2M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Total Liabilities | $111M | $154M | $123M | $116M | $123M | $146M | $146M | $140M | $160M | $169M | $166M | $164M | $197M | $244M | $244M | $222M | |
| Long-term Debt | $35M | $38M | $52M | $48M | $50M | $56M | $58M | $52M | $67M | $61M | $61M | $46M | $55M | $92M | $92M | $91M | |
| Total Debt | $5M | $2M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $33.0K | $33.0K | $31.0K | $31.0K | $30.0K | $30.0K | $28.0K | $28.0K | $23.0K | $19.0K | $15.0K | $9.0K | $132.0K | $130.0K | $7.0K | $108.0K | |
| Paid-in Capital | $788M | $786M | $784M | $786M | $780M | $774M | $764M | $755M | $739M | $733M | $717M | $702M | $699M | $693M | $676M | $669M | |
| Retained Earnings | $-624M | $-624M | $-734M | $-730M | $-736M | $-751M | $-741M | $-734M | $-721M | $-710M | $-695M | $-686M | $-681M | $-656M | $-634M | $-607M | |
| Stockholders' Equity | $164M | $162M | $50M | $56M | $44M | $22M | $23M | $21M | $18M | $23M | $23M | $17M | $19M | $38M | $42M | $62M | |
| Liabilities + Equity | $317M | $357M | $186M | $181M | $160M | $178M | $144M | $127M | $146M | $165M | $168M | $151M | $181M | $264M | $294M | $324M | |
| Shares Outstanding | 33,311,012 | 33,186,671 | 31,364,094 | 31,005,170 | 29,752,795 | 29,554,966 | 27,908,839 | 27,584,600 | 22,587,038 | 19,375,343 | 15,093,053 | 8,937,587 | 131,657,369 | 130,417,161 | 7,366,283 | 108,259,353 |
التدفق النقدي
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $3M | $2M | $2M | $3M | $17M | $6M | $16M | $7M | $5M | $5M | $4M | $4M | $4M | $5M | $6M | $7M | |
| Amort. of Intangibles | $969.0K | $1M | $1M | $1M | $1M | $1M | $982.0K | $814.0K | $814.0K | $814.0K | $815.0K | $814.0K | $1M | $1M | $1M | $1M | |
| Operating Cash Flow | $-59M | $204M | $-13M | $-6M | $-28M | $-20M | $-13M | $-20M | $-22M | $-25M | $-35M | $-17M | $-33M | $-43M | $-48M | $-43M | |
| CapEx | · | · | · | · | · | · | · | $0 | · | · | $28.0K | $1.0K | $34.0K | $0 | $91.0K | $980.0K | |
| Investing Cash Flow | $-79.0K | $0 | $0 | $3M | $6M | $1M | $-15M | $0 | $0 | $0 | $-63.0K | $5M | $-2M | $-5M | $-391.0K | $-893.0K | |
| Stock Issued | · | $0 | $0 | $0 | $-1.0K | $1M | $340.0K | $568.0K | $2M | $894.0K | $-15.0K | $888.0K | $721.0K | $447.0K | $303.0K | $223.0K | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | $894.0K | · | · | · | $447.0K | · | · | |
| Dividends Paid | · | $0 | $166.0K | $166.0K | $166.0K | $166.0K | $166.0K | $176.0K | $176.0K | $176.0K | $180.0K | $185.0K | $185.0K | $186.0K | $186.0K | $188.0K | |
| Financing Cash Flow | $91.0K | $-27M | $6M | $15M | $5M | $52M | $26M | $3M | $14M | $28M | $44M | $-3M | $-30M | $22M | $19M | $4M | |
| Net Change in Cash | $-59M | $176M | $-7M | $12M | $-17M | $34M | $-2M | $-17M | $-8M | $2M | $9M | $-14M | $-66M | $-26M | $-30M | $-40M | |
| Taxes Paid | · | · | $0 | $0 | · | · | $5.0K | $0 | $115.0K | $0 | $-38.0K | $35.0K | $52.0K | $-104.0K | $-604.0K | $1M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | · | · | · | · | $-43M | · | · |
الربحية
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -53.5% | -48.2% | · | -38.6% | -222.2% | -169.8% | · | -151.0% | -186.5% | -280.6% | · | -39.6% | -288.2% | -473.6% | · | -307.0% | |
| Net Margin | -2.5% | 688.2% | · | 33.2% | 94.3% | -80.5% | · | -88.0% | -73.5% | -118.3% | · | -14.5% | -142.5% | -173.3% | · | -136.2% | |
| Pretax Margin | 4.9% | 887.2% | · | 50.2% | · | · | · | -182.0% | · | · | · | -30.4% | · | · | · | · | |
| EBITDA Margin | -53.5% | -48.2% | · | -38.6% | -222.2% | -169.8% | · | -151.0% | -186.5% | -280.6% | · | -39.6% | -288.2% | -473.6% | · | -307.0% | |
| ROA | -0.20% | 41.3% | · | 3.8% | 10.1% | -6.2% | · | -9.3% | -6.7% | -7.2% | · | -2.1% | -9.1% | -6.4% | · | -6.2% | |
| ROE | -0.45% | 119.7% | · | 15.2% | 50.1% | -46.8% | · | -68.0% | -60.2% | -50.7% | · | -12.9% | -51.8% | -31.8% | · | -29.2% | |
| ROIC | -3.9% | -4.5% | · | -12.2% | · | · | · | -104.7% | · | · | · | -83.6% | · | · | · | · |
السيولة والملاءة
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.0 | 2.9 | · | 2.2 | 1.9 | 1.7 | · | 1.2 | 1.4 | 1.3 | · | 1.0 | 1.0 | 1.6 | · | 2.4 | |
| Quick Ratio | 3.8 | 2.7 | · | 1.9 | 1.6 | 1.5 | · | 1.0 | 1.1 | 1.1 | · | 0.8 | 0.7 | 1.4 | · | 2.2 | |
| Debt / Equity | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
الكفاءة
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.6 | 0.6 | · | 0.5 | 0.4 | 0.4 | · | 0.5 | 0.6 | 0.6 | · | 0.5 | 0.6 | 0.4 | · | 0.5 | |
| Receivables Turnover | 0.7 | 0.7 | · | 1.2 | 1.3 | 0.9 | · | 1.6 | 1.1 | 0.7 | · | 1.9 | 0.8 | 0.4 | · | 0.5 |
لكل سهم
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $4.93 | $4.89 | · | $1.80 | $1.48 | $0.75 | · | $0.77 | $0.79 | $1.19 | · | $1.87 | $0.14 | $0.29 | · | $0.57 | |
| Revenue / Share | $0.59 | $0.42 | · | $0.53 | $0.55 | $0.50 | · | $0.74 | $0.81 | · | · | $4.63 | $0.16 | $0.12 | · | $0.18 | |
| Cash Flow / Share | · | $5.31 | · | · | · | $-0.74 | · | · | · | · | · | · | · | $-0.42 | · | · | |
| Cash / Share | $5.90 | $7.71 | · | $2.78 | $2.50 | $3.09 | · | $2.13 | $3.37 | $4.32 | · | $8.09 | $0.59 | $1.17 | · | $1.92 | |
| Dividend / Share | · | · | · | · | · | · | · | $0.00 | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $2.70 | $3.23 | · | $-0.08 | $-0.95 | $-2.13 | · | $-6.20 | $-6.38 | $-9.30 | · | $-16.22 | $-19.39 | $-16.00 | · | $-4.93 |
التقييم (آخر 12 شهرًا)
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $68M | $66M | · | $62M | $59M | $58M | · | $63M | $83M | $85M | · | $81M | $63M | $64M | · | $78M | |
| Net Income TTM | $112M | $128M | · | $4M | $-15M | $-41M | · | $-49M | $-41M | $-55M | · | $-78M | $-96M | $-92M | · | $-91M | |
| Market Cap | $670M | $462M | · | $285M | $229M | $178M | · | $150M | $359M | $322M | · | $105M | $2.30B | $2.40B | · | $2.03B | |
| Enterprise Value | $478M | $208M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 7.4 | 4.3 | · | -115.0 | -8.1 | -2.8 | · | -0.9 | -2.5 | -1.8 | · | -0.7 | -0.9 | -1.1 | · | -3.8 | |
| P/S | 9.8 | 7.0 | · | 4.6 | 3.9 | 3.1 | · | 2.4 | 4.3 | 3.8 | · | 1.3 | 36.7 | 37.4 | · | 26.2 | |
| P/B | 4.1 | 2.8 | · | 5.1 | 5.2 | 8.0 | · | 7.1 | 20.1 | 14.0 | · | 6.3 | 124.5 | 63.5 | · | 32.9 | |
| P / Tangible Book | 4.8 | 3.4 | · | 10.5 | 16.1 | · | · | 45.4 | · | 90.5 | · | · | · | 205.7 | · | 61.1 | |
| P / Cash Flow | · | 2.3 | · | · | · | -9.1 | · | · | · | -12.7 | · | · | · | -55.5 | · | · | |
| EV / Revenue | 7.0 | 3.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend Yield | 0.07% | 0.11% | · | 0.23% | 0.29% | 0.39% | · | 0.47% | 0.20% | 0.23% | · | 0.71% | 0.03% | 0.03% | · | 0.04% | |
| Earnings Yield | 13.4% | 23.2% | · | -0.87% | -12.3% | -35.4% | · | -113.8% | -40.1% | -56.0% | · | -138.3% | -110.8% | -87.0% | · | -26.3% | |
| Payout Ratio | · | 0.00% | · | · | · | -1.6% | · | · | · | -1.1% | · | · | · | -0.86% | · | · | |
| Annual Payout | $498.0K | $498.0K | · | $664.0K | $674.0K | $684.0K | · | $708.0K | $717.0K | $726.0K | · | $742.0K | $745.0K | $748.0K | · | $750.0K |
أحدث فترة على اليسار · القيم الفارغة معروضة كـ ·
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
| المقياس | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|
| الإيرادات | $63M | · | · | $58M | · |
| هامش الربح التشغيلي % | -111.0% | · | · | -191.4% | · |
| صافي الدخل | $7M | · | · | $-46M | · |
| EPS المخفف | $-0.07 | · | · | $-2.69 | · |
| المقياس | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|
| النسبة الحالية | 2.5 | · | · | 1.3 | · |
| النسبة السريعة | 2.2 | · | · | 0.9 | · |
| المقياس | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|
| التدفق النقدي الحر | · | · | · | $-80M | · |
الناشطون والمالكون بنسبة 5%+ 3 حيازات
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| Fortress Biotech, Inc. ×2 إيداعات | 3 يناير، 2025 | 12,40% | تعديل | · | SEC |
| Lindsay A Rosenwald, M.D. | 27 يناير، 2017 | · | إيداع أولي | · | SEC |
| Michael S. Weiss | 28 يناير، 2016 | · | إيداع أولي | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
المطلعون على الشركة 10 من المطلعين · مسؤولون 4 · مديرون 8
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| Lindsay A. Rosenwald, M.D. | President and CEO | 1 يناير، 2017 A | 5857168 | 0 | 0 | $0 |
| David Jin | Chief Financial Officer | 1 أكتوبر، 2026 A | 1652761 | 0 | 0 | $0 |
| Michael S Weiss | Exec. VC - Strategic Dev. | 1 يناير، 2017 A | 8001170 | 0 | 0 | $0 |
| George Avgerinos | SVP, Biologics Operations | 16 سبتمبر، 2016 S | 259088 | 0 | 0 | $0 |
| Kevin Lorenz | مدير | 1 يناير، 2026 A | 101009 | 0 | 0 | $0 |
| Dov Klein | مدير | 14 يوليو، 2017 A | 201668 | 0 | 0 | $0 |
| Jimmie Harvey | مدير | 10 مارس، 2017 A | · | 0 | 0 | $0 |
| Malcolm Hoenlein | مدير | 10 مارس، 2017 A | · | 0 | 0 | $0 |
| Eric K Rowinsky | مدير | 1 يناير، 2017 A | 350000 | 0 | 0 | $0 |
| Jay J Lobell | مدير | 1 يناير، 2017 A | 686000 | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
FBIOP توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
تصنيف · 8 محللين
شراء
2 25,0%
شراء قوي
5 62,5%
شراء
1 12,5%
احتفاظ
0 0,0%
بيع
0 0,0%
بيع قوي
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
أساس السنة المالية، الأسعار كما في إغلاق نهاية السنة المالية الأخيرة لكل شركة.
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| FBIOP | $298M | -135.6 | 9.7% | 10.8% | 18.8% | · |
| ALDX | $312M | -9.2 | · | · | -68.0% | · |
| SPRO | $131M | 15.5 | 39.2% | 12.8% | 18.7% | · |
| RNTX | · | -0.6 | · | · | · | · |
| GRML | · | · | · | · | -104.9% | · |
| FBIO | · | · | · | · | · | · |
| XBIT | · | -1.6 | · | · | · | · |
| APLM | · | -2.5 | · | -128.7% | -1305.4% | · |
| IBIO | $97M | -5.5 | -75.0% | -33044.0% | -65.7% | · |
| GOSS | $724M | -4.1 | -57.7% | -351.5% | 201.8% | · |
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
اختر المقاييس التي تهمك — انقر فوق علامة + بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.
المصدر: إيداع SEC 10-Q بتاريخ أغسطس 13, 2026